The settlement between Johnson & Johnson ($JNJ) and the Justice dept. designed to resolve a probe of J&J's Risperdal marketing practices. The long-running investigation focused on potential off-label marketing of the antipsychotic drug and another psychopharmaceutical, Invega, the WSJ reports.
The deal would have included civil and criminal fines, plus a misdemeanor guilty plea.
Health and Human Services official expressed frustration with some companies' repeat violations--and said the government might turn to new punishments to help deter misbehavior.
At around $1 billion, the J&J deal wouldn't be record-setting; Pfizer ($PFE) agreed to pay $2.3 billion to wrap up off-label marketing allegations involving Bextra and a basket of other drugs, while Eli Lilly's ($LLY) Zyprexa settlement amounted to $1.4 billion.
[Tracy Staton |
No comments:
Post a Comment